Extensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)

Simply Wall St.06-22

In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645252940?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-22 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645252940","market":"sg","top_or_hot":-1,"title":"Extensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)","media":"Simply Wall St.","content":"<div>\n<p>In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Extensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExtensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 17:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1883839398.USD","symbol_name":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the","article_id":"2645252940","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645252940","pubTimestamp":1782120162,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China.\nBeyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","09969":"诺诚健华","BK1574":"生物医药B类股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","LU1880398471.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) ACC","AGIX":"通用人工智能 ETF-AGIX","ARTY":"ISHARES FUTURE AI & TECH ETF","LU1880398554.USD":"AMUNDI FUNDS GLOBAL EQUITY \"A2\" (USD) INC","AIPO":"Defiance AI and Power Infrastructure ETF","BK4211":"区域性银行","RF":"地区金融"},"translate_title":"各地区广泛的奥布替尼数据可能会改变投资诺诚健华医药（SEHK：9969）的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":0.71,"CHAT":0.71,"AIPO":0.82,"RF":1.5,"AGIX":0.71,"09969":0.9},"content_text":"In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China. Beyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful benefit even in challenging settings such as primary central nervous system lymphoma and elderly diffuse large B-cell lymphoma patients. We’ll now examine how this extensive positive orelabrutinib dataset, especially its cross-regional consistency in chronic lymphocytic leukemia, could reshape InnoCare’s investment narrative. The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementInnoCare Pharma Investment Narrative RecapTo own InnoCare, you need to believe orelabrutinib can anchor a broader hematology and autoimmune franchise while the rest of the pipeline scales into that success. The new EHA data deepen the case that orelabrutinib works consistently across regions, which supports the near term catalyst of further approvals and reimbursement decisions, but it does not remove the central risk that the business still leans heavily on a single flagship drug. Among recent news, the NMPA’s acceptance of orelabrutinib’s NDA for primary immune thrombocytopenia looks especially relevant. If approved, this first autoimmune indication would sit alongside the EHA hematology results and the ongoing SLE Phase III as a key test of whether orelabrutinib can move beyond oncology. Together, they frame how quickly InnoCare can reduce concentration risk and justify its substantial R&D spend on autoimmune expansion. Yet against the robust EHA data, the risk that orelabrutinib still concentrates revenue is something investors should be aware of because... Read the full narrative on InnoCare Pharma (it's free!)InnoCare Pharma's narrative projects CN¥3.8 billion revenue and CN¥205.8 million earnings by 2029. This requires 15.1% yearly revenue growth and a CN¥524.5 million earnings decrease from CN¥730.3 million today.Uncover how InnoCare Pharma's forecasts yield a HK$19.62 fair value, a 84% upside to its current price.Exploring Other PerspectivesSEHK:9969 1-Year Stock Price Chart Some of the lowest ranked analysts were already assuming slower growth, with revenue reaching about CN¥3.4 billion and earnings near CN¥412 million by 2029, which is far more cautious than the consensus and could shift again as this new orelabrutinib data are digested.Explore another fair value estimate on InnoCare Pharma - why the stock might be worth as much as 84% more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your InnoCare Pharma research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free InnoCare Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate InnoCare Pharma's overall financial health at a glance.Searching For A Fresh Perspective?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645252940","isCrawlerRequest":true}